Abigail Brooks, MA

An analysis of data from 2 PBC and PSC cohorts suggests fatigue is common, especially in females with PBC, and may be influenced by pruritus.

Scoping review results suggest AUD medications may improve hepatic outcomes in patients with ALD, but limited research exists on such an association.

Our Q1 recap for nephrology spotlights regulatory updates, new clinical trial data, and advancements in xenotransplant.

Study findings suggest use and monitoring of commonly evaluated hepatic biomarkers and fibrosis scores may provide additional prognostic value in PBC.

Our Q1 recap for gastroenterology spotlights regulatory updates, clinical trial data, and new research and guidance about colorectal cancer screening.

Using CURE-CKD Registry data, the analysis showed relatively rapid-onset CKD was common in people with prediabetes, especially with hypertension or ASCVD.

Our Q1 recap for hepatology spotlights regulatory updates, clinical trial data, 2 new guidance documents, and the anniversary of a historic FDA approval.

PBC patients with increased serum IgG levels at initial evaluation experienced faster disease progression and a greater probability of liver-related death.

The March 2025 month in review spotlights an RX Review about USMSTF guidance on bowel prep for colonoscopy, an FDA approval, and clinical trial updates.

Bariatric surgery was associated with improved overall survival at an acceptable health care cost within a 10-year horizon.

The March 2025 month in review spotlights a new episode of Crisis Point about CKD for National Kidney Month and renal FDA news.

Study findings suggest COVID-19 is linked to a greater risk of long-term kidney dysfunction and new-onset advanced CKD than influenza.

The FDA accepted an sNDA for pegcetacoplan for C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis.

The month in review spotlights coverage of the anniversary of resmetirom’s FDA approval and research in autoimmune hepatitis, HBV vaccination, and MASLD.

The Biologics License Application submission for sibeprenlimab is supported by results from the phase 2 ENVISION and phase 3 VISIONARY clinical trials.

The approval is based on data from the phase 3 EAGLE-2 and EAGLE-3 trials.

Positive topline results from PORTOLA show treatment with zetomipzomib resulted in steroid-sparing biochemical remissions in AIH.

Patients with celiac disease had a 2-fold greater risk of developing a chronic liver disease and experiencing major adverse liver outcomes.

In the RADIcAL-1 trial, mpMRI with LiverMultiScan reduced liver biopsies, led to fewer specialist consultations, and improved MASLD diagnosis rates.

The success of community-based point-of-diagnosis HCV treatment in the NOW trial was attributable to collaborative care with an integrated pharmacy team.

The submission is supported by results from the phase 3 DUPLEX Study and the phase 2 DUET Study in adult and pediatric patients with FSGS.

Patients with CKD undergoing radical prostatectomy for prostate cancer experienced greater rates of adverse in-hospital outcomes.

Liver transplants for alcohol-associated liver disease and alcohol-associated hepatitis have increased, but many centers lack necessary resources for care.

Daily screen time exceeding 5 hours was associated with a greater risk of hepatic steatosis in adolescents, partially mediated by BMI.

Retransplantation in elderly patients was associated with a higher risk of DWFG but similar death-censored outcomes to primary transplantation.

Findings suggest cardiometabolic risk factors, diet, exercise, and social determinants of health are associated with HRQoL and fibrosis in MASLD.

Patients with PBC and cirrhosis had a higher comorbidity burden and more acute-care events than those without cirrhosis.

The Kidney Transplant Fast Track evaluation approach was associated with a higher likelihood of waitlisting and fewer disparities by race or ethnicity.

Topline results from the phase 2b ANTHEM-UC study show all 3 doses of once-daily oral icotrokinra met the primary endpoint for clinical response.

Psychosocial interventions reduced depressive symptoms in CKD but did not have a significant impact on patients’ quality of life.